Clinical Cancer Epigenetics publishes papers on all topics that pertain to both cancer and epigenetics and that report findings that can significantly impact cancer diagnosis, prognosis, management, or treatment. All papers (including commissioned articles) are stringently peer-reviewed by at least three independent expert reviewers, and only those that report novel and significant research, and that meet the highest standards of scientific merit and rigor are accepted for publication.
Clinical Cancer Epigenetics publishes original research in the form of Research Articles and Cutting-edge Communications. It also publishes reviews, editorials, and news in the form of Reviews, Mini-reviews, Editorials, Systematic Reviews & Metaanalyses, and New & Noteworthy articles. All translational and clinical aspects of cancer epigenetics will be considered, including those that pertain to biomarkers, clinical trials, drugs and other therapeutics, immunology, inflammation, investigative pathology, metastasis, stem cell biology, and tumor microenvironment. Depending on the level of originality of the findings, accepted manuscript will be published either in Clinical Cancer Epigenetics or in its sister journals Clinical Cancer Epigenetics Journal or the Journal of Clinical Cancer Epigenetics. Similarly, articles that mostly or entirely focus on the basic aspects of cancer epigenetics will be after consultation with the authors transferred to the Cancer Epigenetics journal series.
Clinical Cancer Epigenetics has taken on to promoting research transparency and reproducibility to the highest possible level, and thus publishes only articles in the top tier of the publication Reproducibility index (Ri). Therefore, only articles with sufficient statistical power, sample size, biological replicates and controls will be considered. Unless reagent specificity was irrefutably substantiated in a previous publication, published reports that merely claim specificity and have not met our burden of proof will not be taken into consideration in assessing specificity, independently of the number of such published reports. In these cases, reagent specificity has to be demonstrated to the highest approximation of certainty in the submitted paper. Finally, we encourage authors with a translational focus to provide relevant in vivo data to support organismal pathophysiological relevance. If data derived from such models are included, authors are requested to justify the adequacy and choice of the model in the epigenetic and/or neoplastic context investigated.
To submit your paper, please read first our instructions to authors; there are valid for all of the Cancer Epigenetics Society journals. You may otherwise submit your paper at this page.